Description

HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity[1].–Applications-COVID-19-immunoregulation-Formula-C38H45N9O6S2-Citation–References-[1]He L, et al. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021;64(21):15716-15726.-CASNumber-2939851-67-7-MolecularWeight-787.95-Compound Purity–SMILES-C[C@H](COC(NC1=CC=C(C[N+](C)(C)CC2=CC=C(CC3=CC=C(N=C(N)N=C4NCCCC)C4=N3)C=C2)C=C1)=O)SSC5=NC=C([N+]([O-])=O)C=C5.[H]C([O-])=O-Research_Area-Cancer; Infection-Solubility-10 mM in DMSO-Target-Drug-Linker Conjugates for ADC;PD-1/PD-L1;Toll-like Receptor (TLR)-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Immunology/Inflammation-MCE Product type-ADC Related